Hepatitis C virus (HCV), the major etiologic agent of "non-A, non-B hepatitis" was discovered 26 years ago. Even before its discovery, interferon-α (IFN) was already being used for treatment of this infection. The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals -DAAs) to that regimen. DAAs target multiple steps in the HCV life cycle and are now used in combination to treat HCV infection without the need of IFN. These IFN-free, oral DAAs regimens are highly efficacious, have minimal toxicity and are given for short duration. Approved DAAs can cure more then 90% of persons with chronic HCV infection, thereby reducing the risk of death from cirrhosis and hepatocellular carcinoma. However, these drugs are very expensive, and currently their exorbitant cost significantly restricts the access to this therapy for many HCV infected patients.
Introduction
HCV is a blood-borne virus, capable of causing both acute and chronic hepatitis, ranging in severity from a mild self-limiting illness to a serious, lifelong illness. [1] [2] [3] [4] [5] World Health Organization (WHO) estimates that 130 to 150 million people globally have chronic hepatitis C infection (CHC). [1] While HCV is found worldwide, certain countries have extreme HCV disease burden (e.g., Egypt). Africa and Central and East Asia have the highest prevalence of CHC, where inadequate sterilization of re-usable medical equipment and transfusion of unscreened blood or blood products have been the predominant modes of HCV transmission. [1, 2] In developed countries, CHC is concentrated in certain populations such as injection drug users (IDA). [1] [2] [3] HCV causes both acute and chronic infection. [1] [2] [3] [4] [5] Patients with acute HCV infection are often asymptomatic or have nonspecific symptoms (fatigue, abdominal pain, nausea) that frequently are not recognized as being associated with acute HCV infection. [2, 3] A small proportion (< 25%) of patients with acute HCV infection will develop jaundice, however acute liver failure is very rare (< 1%). [2] [3] Acute HCV infection is usually self-limited illness. About 20-50% of infected persons spontaneously clear the virus within 6 months of infection without any treatment. [1] [2] [3] [4] [5] The remainning 50-80% of persons will develop CHC. Many of them lack specific symptoms, and are unaware of the presence of this infection. People with CHC are at increased risk for impairments in quality of life, extra-hepatic complications (e.g., mixed cryoglobulinemia, membranoproliferative glomerulonephritis, porphyria cutanea tarda, etc.), and liver-related morbidity and mortality. [1] [2] [3] [4] [5] CHC causes cirrhosis, liver failure and heaptocellular carcinoma and is currently the most common reason for liver transplantation in many countries of the world. [1] [2] [3] [4] [5] According to WHO, HCV is responsible for approximately 500 000 deaths each year globally. [1, 2] HCV infection is curable and complications can be prevented. Until 2 years ago, the treatment of HCV was suboptimal, but it changed dramatically with the introduction of directly acting antivirals (DAAs). This review focuses on the approved DAAs and the current HCV treatment recommendations.
Virology and HCV life cycle
HCV is a small (55 nm in diameter), roughly spherical ribonucleic acid (RNA) virus in the genus Hepacivirus of the Flaviviridae family. [2] [3] [4] [5] There are six major viral HCV genotypes (or clades), numbered 1 to 6. The genotypes are divided into subtypes; however, this subdivision is of clinical importance only for genotype 1 (subtypes 1a and 1b). [2] [3] [4] [5] In the United States and in Europe, genotype 1 is the most common (70 to 80 percent), followed by genotypes 2 and 3. Different genotypes may predominate in other countries (e.g., genotype 4 is the major genotype in Egypt). [1] [2] [3] [4] [5] The genome of HCV is a positive-sense, single-stranded RNA molecule approximately 9.6 kb in length, which contains a large open reading frame (ORF) that encodes a single large polyprotein (≈3010 amino acids). [2] This polyprotein is processed by host-cellular and viral proteases into 10 proteins. [2] There are 3 "structural" proteins [the nucleocapsid protein, core (C), and two envelope proteins (E1 and E2)], 2 proteins that are essential for virion production but not required for viral RNA replication (p7 and NS2); and 5 nonstructural (NS) proteins that form the viral RNA replicase complex (NS3, NS4A, NS4B, NS5A, and NS5B) ( The virus enters the cell through interaction with many cell surface receptor molecules (such as CD81, the LDL receptor, the EGF receptor, the tight junction proteins claudin-1, etc.). [2, 4, 5] Following the viral entry into the cell, the RNA is released into the cytoplasm, where it acts as messenger RNA directing the translation of the viral polyprotein. Because HCV does not replicate through DNA intermediary, it does not integrate into the host genome. The HCV polyprotein undergoes a series of translational and posttranslational proteolytic cleavages. The HCV replicase complex (composed of NS3, NS4A, NS4B, NS5A, and NS5B) forms "membranous web" and directs the synthesis of a negative-strand copy of the RNA. This RNA then serves as a template for the subsequent synthesis of multiple copies of the positive-strand genomic RNA. The RNA is packaged into new viral particles, which are then released from the host cell. The liver is the primary source of virus present in blood, with minority of virus replicating within peripheral mononuclear cells. HCV replicates at a very high rate; approximately 10 12 virions are produced each day in a chronically infected person, which is 10-to 100-fold higher then in HIV infection. The high level of virion turnover together with the absence of proofreading by the NS5B RNA dependent RNA polymerase (RdRp) lead to evolution of multiple variants ("quasi-species") in an infected individual. [2] Treatment for hepatitis C The goal of HCV treatment is eradication of the virus from the host. [2] [3] [4] [5] This is known as a virological cure. Sustained virological response (SVR) is a surrogate for virologic cure. SVR is defined as undetectable HCV RNA in blood 12 weeks or more after treatment has finished. [2] [3] [4] [5] An SVR prevents the development of cirrhosis and other HCV related complications. [2] [3] [4] [5] In patients who already have cirrhosis, an SVR reduces the risks of decompensated cirrhosis and hepatocellular carcinoma, and death, and may eliminate the need for liver transplantation. [2] [3] [4] [5] Current treatment of CHC is rapidly evolving. [2] [3] [4] [5] For the past decade, the standard of care for treatment of CHC had been a combination of subcutaneously-injected pegylated interferon (peg-IFN) and ribavirin administered for 24 (genotypes 2 and 3) or 48 weeks (genotype 1). [2] [3] [4] [5] [6] This combination produces SVR in 40-50% HCV genotype 1 infected patients and 60-70% in genotypes 2 and 3. [2-6] Addition of the first-wave first-generation of HCV protease inhibitors (telaprevir and boceprevir) to peg-IFN and ribavirin increases SVR to 60-75% in HCV genotype 1 infected patients. [2, [4] [5] [6] [7] The use of nucleotide analogue (sofosbuvir) with peg-IFN and ribavirin produces further improvement of SVR [2, 4, 5, 9] .
However the widespread use of peg-IFN containing regimens has been limited by treatment-related toxicity (e.g., flu-like symptoms, malaise, psychiatric disorders, blood counts abnormalities, autoimmune disorders and injecttion site reactions). [2] [3] [4] [5] [6] [7] [8] [9] In addition, peg-IFN and ribavirin regimens are contraindicated in the presence of decompensated cirrhosis, uncontrolled depression, and autoimmune disease. [2] [3] [4] [5] These 2 factors have created a large pool of patients with CHC who are peg-IFN and ribavirin intolerant or ineligible. Before the approval of DAAs, these patients previously had no treatment options. [2] [3] [4] [5] DAAs targeting multiple steps in the HCV life cycle have been developed and are used in combination to successfully treat hepatitis C infected persons (Table  1) . [2] [3] [4] [5] These IFN-free regimens are highly efficacious, have minimal toxicity and are given for short duration. High SVR rates are observed, even in patients with characteristics previously associated with having lower response rates: high HCV RNA levels, infection with genotype 1a, co-infection with HIV, elderly, African American, and those who failed treatment with first-wave first-generation of HCV protease inhibitors (telaprevir and boceprevir). [2] [3] [4] [5] It is now clear that IFN-free regimens are the future of HCV treatment for the majority of patients. Our goal should be treatment of all persons with CHC if they wish and are ready to start treatment and are suitable candidates for treatment. [3, 5] The website HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, from the American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA (AASLD/IDSA/IAS-USA http://www.hcvguidelines.org/ and the European Association for the Stydy of the Liver (EASL) HCV guidelines recommend treatment for all patients with chronic HCV infection, except for those whose life expectancy is less then 12 months due to severe co-morbidities. [3, 5] If treatment is not readily available due to cost or other factors, the highest priority (immediate treatment) should be given to HCV infected patients at highest risk for liver-related complications such as patients with advanced fibrosis (Metavir F3) or compensated cirrhosis (Metavir F4), liver transplant recipients, and patients with severe extrahepatic hepatitis C (mixed cryoglobulinemia, or membranoproliferative glomerulonephritis), followed by patients at higher risk for future complications including those with advanced liver fibrosis (Metavir F2), coexisting liver disease, HIV co-infection, HBV co-infection, insulin resistant diabetes mellitus, debilitating fatigue, and porphyria cutanea tarda. [3, 5] Current treatment recommendations for treatment naïve and previously treated patients with HCV infection, by genotype, cirrhosis status are available at HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C AASLD/IDSA/IAS-USA, and EASL websites, and are regularly updated as new drugs are approved and new evidence about efficacy and safety of the therapies becomes available (Table 2) . Clinicians should always consult these websites for most up-to-date recommendations before treating HCV patients. [3, 5] 
Directly acting antivirals (DAAs) and mechanism of action of DAAs
The HCV replication can be blocked at many steps. [2] [3] [4] [5] Currently approved oral DAAs include NS3-4A protease inhibitors, nucleotide analogue inhibitors of the NS5B RNA-dependent RNA polymerase (RdRp), non-nucleoside inhibitors of the NS5B RdRp and inhibitors of the NS5A protein (See Table 1 ). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] NS3-4A protease inhibitors bind the catalytic site of the enzyme and block the proper cleavage of the viral polyproteins. [2, [4] [5] [6] 8] The first-wave, first-generation NS3-4A protease inhibitors, telaprevir and boceprevir, are only active against genotype 1, have a low barrier to resistance, and high pill burden and numerous side effects. The second-wave, first-generation NS3-4A protease inhibitors (e.g., simeprevir, paritaprevir, and asunaprevir) have broader genotypic activity (genotypes 1, 2, and 4, but not genotype 3), lower pill burden, but still a low barrier to resistance. The second-generation NS3-4A protease inhibitors (e.g., grazoprevirnot yet approved) have pangenotypic activity and an increased barrier to resistance. [4] Nucleotide analogues mimic the naturally occurring nucleotides, and during the viral replication, they incorporate into the newly synthesized viral RNA causing chain termination. [2, 4, 5, 9] Approved nucleotide analogue sofosbuvir has pangenotypic antiviral activity and a high barrier to resistance. [4, 5, 9] Non-nucleoside inhibitors of RdRp bind directly to the enzyme and altering its conformation and its function. [2, 4, 5] Approved non-nucleoside RdRp inhibitor dasabuvir is active against HCV genotype 1 and has a low barrier to resistance. [4] NS5A inhibitors bind the NS5A protein and block its ability to regulate HCV replication within the replication complex and inhibit assembly and release of viral particles. [2-5, 10-12] The first-generation NS5A inhibitors (e.g., ledipasvir, daclatisvir, ombitasvir) have varied genotypic activity and a low barrier to resistance. [4, 5, [10] [11] [12] The second-generation NS5A inhibitors (e.g., elbasvir-not yet approved) have pangenotypic activity, and an increased barrier to resistance compared to first-generation agents. [4] Select DAAs
NS3-4A protease inhibitors
This drug class is specifically designed to inhibit the NS3/4A HCV protease. These agents resemble the HCV polypeptide and, when processed by the viral protease, form a covalent bond with the catalytic NS3 serine residues, block further activity, and prevent proteolytic cleavage of the HCV polyprotein into NS4A, NS4B, NS5A, and NS5B proteins.
Telaprevir (Incivek -manufactured by Vertex Pharmaceuticals) and boceprevir (Victrelismanufactured by Merck), the first wave, first generation NS3/4A HCV protease inhibitors were significant advance in treatment of with HCV genotype 1 infected patients during the years 2011 to 2013. [4] [5] [6] [7] [8] Clinical studies in treatment-naïve patients and previously treated with peg-IFN and ribavirin showed that the addition of telaprevir or boceprevir improved SVR to 60-75% [4] [5] [6] [7] [8] , However, this improvement was at the cost of increased adverse effects. [4, 5, 8 ] The addition of telaprevir or boceprevir to peg-IFN and ribavirin increases the risk of anemia. [6] [7] [8] Telaprevir causes occasional severe skin rashes and GI symptoms. [6] [7] High pill burden is another problem. The recommended dosage of telaprevir is 1125 mg (three 375 mg tablets) twice daily and for boceprevir is 800 mg (four 200 mg capsules) three times daily. [6] [7] [8] Major drug-drug interactions are common as these drugs are both substrates and inhibitors of cytochrome P-450 3A4 (CYP3A4) and P-glycoprotein (P-gp). [6] [7] [8] Lastly, the rapid development of resistance with virologic breakthrough and availability of new DAAs (sofosbuvir and simeprevir) created a situation where telaprevir and boceprevir are very unlikely to be used in any of the future HCV therapies. [4] [5] Simeprevir Simeprevir (Olysio -Manufacturer by Janssen Pharmaceuticals) is a second wave, first generation NS3/4A HCV protease inhibittor, active against genotype 1 (1b > 1a). [4] The efficacy of simeprevir has been evaluated in several open label and controlled trials of both treatment-naïve and treatment-experienced patients with chronic HCV genotype 1 infection. [4, 5, 8] Addition of simeprevir to peg-IFN/ribavirin or to sofosbuvir produced significantly higher SVR rates compared to placebo or historic controls in all of the trials. [4, 5, 8] However, the efficacy of simeprevir was reduced in genotype 1a HCV infected patients who had the NS3 Q80K polymorphism at baseline (approximately one-third of US patients in the clinical studies). [4, 5, 8 ] Therefore, it is recommended that testing for Q80K be performed before treatment with simeprevir for treatment of HCV 1a genotype. Alternative therapy should be used for those who have it. [4, 8] The recommended dosage of simeprevir capsule is 150 mg once daily with food. [8] Simeprevir is nearly entirely bound by plasma proteins and cleared by biliary excretion. Because there is no renal excretion, dose adjustments are not required in the presence of renal dysfunction. Simeprevir is a substrate and inhibitor of intestinal CYP3A and P-gp. [8] Simeprevir should not be administered with moderate or strong inhibitors or inducers of CYP3A. [8] Simeprevir is better tolerated then the first wave, first generation NS3/4A HCV protease inhibitors. Rash and photosensitivity (affecting quarter of recipients) and mild reversible isolated hyperbilirubinemia are the most common side effects. [8] Nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase Sofosbuvir Sofosbuvir (Sovaldi) is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase (RdRp). [4, 5, 9] Sofosbuvir is a prodrug that undergoes intracellular metabolism in the liver (phosphorylation) to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into newly synthesized RNA primer strand by the RdRp polymerase and acts as a chain terminator. [4, 9] It is pangenotypic in its anti-HCV activity and has a high barrier for resistance. [4, 9] Manufacturer is Gilead Sciences, which has co-formulated sofosbuvir with ledipasvir in fixed dose combination pill Harvoni. [9, 10] At the present time, sofosbuvir serves as a "backbone" for several of the DAAs treatment regimens. [3] [4] [5] It has been studied in combination with peg-IFN and RBV, and in IFN-free regimens with ribavirin, or with simprevir, or with daclatasivir or ledipasvir. [3] [4] [5] [9] [10] [11] [12] The recommended dosage of sofosbuvir tablet is 400 mg once daily without regard to food. [3, 9] Sofosbuvir is extensively metabolized in the liver to form the active metabolite GS-461203, and also the inactive metabolite GS-331007. [9] . Sofosbuvir is a substrate of drug transporter P-gp. Only clinically significant drug interaction is with drugs that are P-gp inducers in the intestine (e.g., rifampin or St. John's wort), which may decrease sofosbuvir plasma concentration and it's therapeutic effect, and thus concomitant use with sofosbuvir is not recommended. [9] Approximately 80% of sofusbuvir and its inactive metabolite (GS-331007) are excreted in the urine. [9] A 4-hour hemodialysis session removes approximately 18% of administered dose. No dosage adjustment is required for patients with mild or moderate renal impairment, but no dosage recommendation are given for patients with severe renal impairment or ESRD. [9] There is substantial accumulation of the sofosbuvir-inactive metabolite (GS-331007) in ESRD, with unclear clinical conesquence. [3, 9] Sofosbuvir is generally well tolerated with headache and malaise being the most common side effects in the clinical trials. [9] Post marketing surveillance elicited reports of serious symptomatic bradycardia when sofosbuvir (together with other DAAs) were co-administered with amiodarone. The onset was within days of commencing the HCV regimen. [13] The mechanism of this effect is unknown at this time but most of the patients had advanced liver disease (possibly leading to above-normal amiodarone levels) and were receiving beta-blockers [13] . The new labels of sofosbuvir -containing regimen state that coadministration of amiodarone with is not recommendded, but if coadministration is necessary, close cardiac monitoring is recommended for the first 2 weeks of starting DAAs. [13] Inhibitor of nonstructural protein 5A (NS5A) Daclatasvir Daclatasvir (Daklinza) is an inhibitor of NS5A, a nonstructural protein encoded by HCV. Daclatasvir binds to the NS5A (palm domain 1 region of the protein) causing structural distortions that interfere with NS5A functions, inhibiting both viral RNA replication and virion assembly. [4, 12] Daclatasvir has activity against all genotypes, especially genotypes 1, 2, and 3, and lesser activity against genotypes 4, 5 and 6.
[12] It has a low barrier for resistance. [4] Cross resistance between daclatasvir and other NS5A inhibitors is expected. Cross-resistance between daclatasvir and other classes of directacting antivirals is not expected. [4] Daclatasvir is currently approved for use in Europe in combination with other anti-HCV agents for genotypes 1, 2, 3, and 4. It was approved in the USA in July 2015 for use with sofosbuvir for the treatment of chronic HCV genotype 3 infection. [4, 12] . Manufacturer of daclatasvir, BristolMyers Squibb (BMS) is currently studying daclatasvir as a component of a fixed-dose combination pill (daclatasvir-asunaprevir-beclabuvir with or without ribavirin). [4] Daclatasvir is available as a 60 mg tablet and 30 mg tablet. The recommended dose of daclatasvir is 60 mg orally once daily, without regard to food. [12] Daclatasvir is a substrate of CYP3A4, and moderate inhibitor of P-gp. [12] Daclatasvir use is contraindicated in combination with drugs that strongly induce CYP3A (phenytoin, carbamazepine, rifampin, and St. John's wort etc.), which may lead to lower exposure and loss of efficacy of daclatasvir. [12] Dose adjustments for daclatasvir in patients receiving strong inhibitors, and moderate inducers of CYP3A are predictable. This makes this drug very valuable in HIV-HCV co-infected patients receiving antiretroviral (anti-HIV) therapy or transplant recipients with HCV of the allograft. [3, 4, 12] When given concomitantly with a strong CYP3A inhibitor (clarithromycin, ritonavir, voriconazole etc.), the daclatasvir dose should be reduced to 30 mg once daily. [3, 12] When given with moderate cytochrome P-450 3A4 inducers (dexamethasone, efavirenz, etravirine etc.), the DCV dose should be increased to 90 mg once daily. [3, 12] No dosage adjustment of daclatasvir is required for patients with any degree of hepatic impairment or renal impairment. [12] Daclatasvir is well tolerated, and most common adverse reactions (≥ 10%) observed in combination with sofosbuvir were headache and fatigue. [12] Daclatasvir, as with any other DAAs when coadministered with sofosbuvir, and amiodarone may cause serious bradycardia. [12, 13] Fixed dose formulations Harvoni (ledipasvir / sofosbuvir) Sofosbuvir is a nucleotide analog inhibitor of the NS5B RNA-dependent RNA polymerase. Ledipasvir is an inhibitor of NS5A, a nonstructural protein encoded by HCV. It has potent activity against genotypes 1, 4, and 6, but less activity against genotypes 2, 3 and 5. [4, 10] . It has a low barrier for resistance similar to the other first generation NS5A inhibittors. [4] Manufacturer is Gilead Sciences. Ledipasvir is not available as a stand-alone tablet, but is coformulated with sofosbuvir, in a fixed-dose combination pill called Harvoni. Each Harvoni tablet contains 90 mg ledipasvir and 400 mg sofosbuvir. [10] It is administered once daily, without regard to food. [10] It was FDA-approved in 2014 as the first peg-IFN and ribavirin-free single pill regimen to treat CHC. Ledipasvir and sofosbuvir are substrates of drug transporters P-gp, and concomitant use with P-gp inducers (e.g., rifampin, carbamazepine or St. John's wort) is not recommended because it may lead to decreased ledipasvir and sofosbuvir plasma concentrations and lower therapeutic effect. [10] Additionally, ledipasvir absorption is significantly decreased with concurrent use of acid reducing agents. [10] It is recommended to separate antacid and Harvoni administration by 4 hours. Proton pump inhibitors (dose limited the equivalent of 20 mg omeprazole) should not be taken before Harvoni but should be taken at the same time (simultaneously). [10] Coadministration of amiodarone with Harvoni may result in serious symptomatic bradycardia [10, 13] . Concurrent use simeprevir, which is a substrate and inhibitor of P-gp, and ledipasvir has been shown to increase serum concentrations of both drugs and is also not recommended. [10] Harvoni also increases serum concentrations of tenofovir, and may potentiate the nephrotoxicity of tenofovir disoproxil fumarate, especially with coadministered with other antiretroviral drugs that raise tenofovir levels (e.g., ritonavir-boosted HIV protease inhibitors). [10] For patients with mild, moderate, or severe hepatic impairment, no dosage adjustment is recommended, as is for patients with mild to moderate renal impairment.
[10] However, there are no dose recommendations for patients with severe renal impairment (eGFR less than 30 ml/min/1.73m 2 ) or end-stage renal disease (ESRD) requiring dialysis. [10] This is related to sofosbuvir, whose inactive metabolite accumulates in excess in patients with very decreased GFR. (See sofosbuvir for details). Harvoni is well tolerated with headache and malaise being the most common side effects. [10] Viekira Pak (USA); Holkira Pak (Canada and other countries) (paritaprevir/ritonavir/ombitasvir and dasabuvir) Viekira Pak (manufactured by Abbvie) is a 4-drug combination product that contains 3 DAAs (paritaprevir, ombitasvir and dasabuvir) with the pharmacologic enhancer ritonavir (used to increase the exposure of paritaprevir). [3, 4, 11] This regimen is also called "3D regimen", and resembles the treatment of HIV infection, where antiretroviral agents with different mechanisms of action are combined in order to increase efficacy and prevent evolution of resistance. Each DAA in Viekira Pak targets an HCV protein that is essential for viral replication. [11] Paritaprevir inhibits the HCV NS3/4A protease. Ombitasvir inhibits the NS5A protein. Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase (NS5B protein). [11] Viekira Pak contains a fixed-dose combination of paritaprevir, ritonavir and ombitasvir in one tablet, and dasabuvir in a second tablet. It is administered 2 tablets (paritaprevir/ritonavir /ombitasvir 75/50/12.5 mg) once daily (in the morning) and 1 tablet dasabuvir 250 mg-twice daily (morning and evening) with food. Viekera Pak is FDA approved for treatment of HCV genotype 1 infection. Abbvie also markets Technivie, which in essence is Viekera Pak without dasabuvir. It is FDA approved for treatment of genotype 4 HCV infection together with ribavirin. Viekira Pak is well tolerated with fatigue, nausea, insomnia and skin reactions being the most common adverse effects. [11] Approximately 1% of subjects receiving Viekira Pak in clinical trials, developed elevated alanine aminotransferase (ALT) > 5 x upper limit of normal. The labeling carries a warning alerting patients and clinicians of the risk of ALT elevation and recommends ALT testing during the first four weeks of starting treatment, and as clinically indicated thereafter.
[11] Viekira Pak is contraindicated in patients with severe hepatic impairment due to risk of potential toxicity. However, no renal dose adjustment is needed.
Viekira Pak, being a 4-drug combination has multiple drug interactions. Ritonavir as a strong CYP3A4 inhibitor will "boost" many drugs that are CYP3A4 substrates. Some drugs such as ergot alkaloids, lovastatin, simvastatin, pimozide, triazolam, and midazolam are contraindicated for use with Viekira Pak; some require dose reduction (e.g., cyclosporine and tacrolimus). Paritaprevir is CYP3A4 substrate and dasabuvir is CYP2C8 substrate. Viekira Pak is contraindicated with inducers of CYP2C8 or CYP3A4 or strong CYP3A4 inhibitors (e.g., rifampin, carbamazepine, rilpivirine, efaverenz, ritonavir-boosted darunavir or lopinavir, longacting inhaled beta-adrenoceptor agonist salmeterol). [3, 11] Clinicians should consult the labeling information and other resources (e.g., http://www.hep-druginteractions.org/) to ensure safety when prescribing this (and other DAA) regimens. [3, 11] Resistance to DAAs Evolution of resistance to DAAs is inevitable as is the case with any of the antimicrobial agents developed for clinical use. Risk factors for resistance to DAAs include suboptimal adherence to the medication regimen, pharmacokinetic interactions leading to lower blood levels of DAAs and advanced fibrosis. [3, 4] Clinical studies and real-world experience of using DAAs have revealed that resistant associated variants (RAVs) can be detected during on-treatment virologic breakthrough or after completion of treatment in persons with relapse of HCV infection. [3, 4] These RAVs are of particular clinical relevance for NS5A inhibitors and to lesser degree the NS3/4 protease inhibitors. [3, 4] The NS5A inhibitor RAVs are crossresistant to all of the approved agents in this class (daclatasvir, ledipasvir, and ombitasvir), and appear to persist for extended time. [4] Resistance testing is a useful tool in selecting the next treatment regimen in patients who experienced treatment failure using NS5A inhibitors and / or NS3/4 protease inhibitors and who urgently need to be treated (who can not await the approval of the next generation DAAs; e.g., patients with cirrhosis). [4] The commercially available assays test for RAVs to NS5A inhibitors and NS3/4 protease inhibitors. This recommendation is now available in the updated HCV treatment guideline [3] . Management of patients who have failed (relapsed after) DAA therapy is rapidly evolving, and current guidelines recommend treating such patients with different classes of DAAs based on the results of resistance testing (exception is sofosbuvir, which can be used in re-treatment regimen), for longer duration of time (24 weeks instead of 12 weeks) and with the addition of ribavirin. [3, 4] renal function tests including eGFR, assays to detect HIV and HBV coinfection, blood HCV RNA level, and HCV genotype and subtype. [3] Staging of liver fibrosis is recommended to determine the urgency for treatment, to screen for complications of cirrhosis such as esophageal varices and hepatocellular carcinoma, and occasionally to satisfy the payer (USA heath insurance) requirement. This can be accomplished by certain biomarkers (e.g., FibroSure), imaging modalities (MRI, ultrasound), transient elastography (FibroScan) and liver biopsy. The patients should be advised on hepatoprotective measures, including avoidance of hepatotoxins, weight reduction if obese, and immunizations against hepatitis A and B. Assessment of potential drug-drug interactions with concomitant medications and counseling regarding the importance of adherence are recommended prior to starting HCV therapy. Upon starting treatment, "safety" labs (LFTs, eGFR, CBC) should be done at 4 week and as needed there after. Quantitative HCV viral load testing is recommended after 4 weeks of therapy, end of therapy and at 12 weeks following completion of therapy. [3] Patients with advanced fibrosis or cirrhosis should undergo ultrasound testing every 6 months as surveillance for hepatocellular carcinoma, and endoscopic surveillance for esophageal varices (if cirrhotic). [3] . Serum pregnancy testing is recommended for women of childbearing age prior to beginning treatment, especially if the regimen includes ribavirin. [3] Cost of DAA regimens Cost of the DAA regimens for treatmentnaive and treatment-experienced HCV infected non-cirrhotic and cirrhotic patients in the USA ranges from approximately $63,000 to $300,000. [3, 16] The common answer to the high price of DAAs by the various payers (insurers) has been to restrict the access to therapy, usually based on the severity of liver disease. [3, 4, 16] . However the rationing of DAAs has a different flavor when compared to other rationing decisions in healthcare, such as organ transplanttation, where supply is limited. [16] Rationing DAAs in the USA represents a decision to allocate finite healthcare dollars to corporate profiteering instead of curing patients. [16] The very high cost of the DAAs is a major obstacle to its widespread use at this time and may lead to downfall of HCV elimination strategies. [4, 16] 
Conclusion
In the past 2 years, the approval of several DAAs has dramatically changed the management of patients with chronic HCV infection [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . HCV can now be cured in over 90% of patients, using a well-tolerated oral therapy with low pill burden and short treatment duration. Ongoing challenges include treatment of select populations (e.g., patients with end-stage renal disease and decompensated cirrhosis), cost of the medications and access of care, and increasing resistance to DAAs. Fortunately, the HCV therapeutic pipeline is rich and more DAAs are expected to be approved over the next years, including pangenotypic dual-and triple-DAA regimens, with higher barriers for resistance, that produce SVR rates over 95% after a treatment duration of less then 8 weeks, and are well tolerated in all populations and may not require dose adjustment for renal or hepatic failure.
